Femasys announces first-patient-in for pivotal clinical trial evaluating its fembloc permanent birth control

Atlanta, sept. 20, 2023 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including two lead revolutionary late-clinical stage product candidates and fda-cleared, innovative diagnostic products, today announced the achievement of first-patient-in for its pivotal clinical trial evaluating fembloc®, a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control for women. the landmark pivotal clinical trial (the “finale” trial) is currently enrolling patients and additional clinical sites are planned to support the further expansion of the trial.
FEMY Ratings Summary
FEMY Quant Ranking